Latest Racing News

BetMakers Technology Group has signed a definitive agreement to acquire Las Vegas Dissemination Company, gaining direct access to major Nevada casino operators and projecting $4.5 million revenue in the first year.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

InhaleRx has boosted its funding facility by $12.6 million to accelerate clinical trials of SRX-25, a novel oral treatment for Treatment-Resistant Depression. This brings total available capital to $52.3 million, positioning the company for pivotal Phase III studies.

Predictive Discovery has received a compelling unsolicited acquisition proposal from Perseus Mining, valuing the company at A$2.1 billion and triggering a competitive matching period with Robex Resources.

BetMakers Technology Group has secured a favorable three-year content distribution agreement with Penn Entertainment, alongside strong digital customer growth that signals robust momentum for FY26 and beyond.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.

Battery Age Minerals has appointed DGWA as its European strategic advisor to advance the Bleiberg Zinc Germanium Project within the EU’s Critical Raw Materials Act framework, initiating high-level engagements across key EU capitals.

Evion Group has landed a significant A$1.5 million order to supply expandable graphite to a major US graphite supply chain company, reinforcing its position as a trusted non-Chinese supplier amid growing demand.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

Sports Entertainment Group (SEG) reported a 62% jump in underlying EBITDA for FY25, underpinned by strong margin expansion and operational leverage. The company reaffirms its optimistic FY26 outlook with double-digit EBITDA growth expected.

Airtasker Limited showcased strong FY25 financials and unveiled aggressive growth plans in the UK and US, supported by strategic media partnerships and core platform investments.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.